WithdrawnNCT05991622
Combined Injectable Treatment for HIV and OUD
Medication studyAges 18–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
What will I do during this study?
The protocol includes: Completing questionnaires.
- Listed locations
- ProvidenceSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 1, 2022
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Rhode Island Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05991622
- Official title
Show the full official title
Integrating Long-Acting Injectable Treatment to Improve Medication Adherence Among Persons Living With HIV and Opioid Use Disorder
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Providence
Interested in joining this study?
Questions about this study
What will I need to do?
You will complete questionnaires.
Who is behind this study?
The study sponsor is Rhode Island Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Combined LAI Treatment: Cabenuva and Sublocade.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
